Initiate post-transplant maintenance trial for iberdomide in multiple myeloma
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Jan 2023
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“post-transplant maintenance trial planned for 2023 in multiple myeloma”
What we found
Evidence strength A What the grades mean
The company's SEC filings from early 2024 confirm that the post-autologous stem cell therapy maintenance trial for iberdomide in multiple myeloma was included in their clinical development portfolio.
-
A Bristol Myers Squibb Co. 8-K filed 2024-01-08
“iberdomide ª2L+ Multiple Myeloma Post-Autologous Stem Cell Therapy Maintenance Newly Diagnosed Multiple Myeloma” ✓ confirmed on the page
Market reaction: the shares moved -4.9% against the S&P 500 over the three sessions around the disclosure (5 Jan 2024 to 10 Jan 2024). What this measures
Checked 4 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- post-transplant maintenance trial for iberdomide
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Bristol Myers Squibb Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-BMY-004573 · Corrections policy